NCT03570346 is a Phase 1 clinical trial of Hemay005 in Psoriasis, sponsored by Tianjin Hemay Bio-Tech Co., Ltd.

Who is sponsoring NCT03570346?

NCT03570346 is sponsored by Tianjin Hemay Bio-Tech Co., Ltd.

What drugs are being tested in NCT03570346?

Interventions in NCT03570346: Hemay005, Placebo.

Is NCT03570346 still recruiting?

NCT03570346 is currently status unknown. Last updated 2 October 2018.

Last reviewed 2018-10-02 · How we verify

NCT03570346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

Status unknown Phase 1 Last updated 2 October 2018

What this trial tests

Phase 1 trial testing Hemay005 in Psoriasis in 24 participants. Status unknown.

Timeline

10 July 2018

Primary endpoint
20 October 2018

1 December 2018

Quick facts

Lead sponsor	Tianjin Hemay Bio-Tech Co., Ltd
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	10 July 2018
Primary completion	20 October 2018
Estimated completion	1 December 2018
Sites	1 location across China

Drugs / interventions tested

Hemay005 — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Tianjin Hemay Bio-Tech Co., Ltd

Who can join

Adults 18 to 60, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. A total of approximately 24 subjects will be randomized into 3 cohorts(15mg, 30mg, 60mg), approximately 8 healthy subjects will be enrolled (6 active and 2 placebo) at each dose cohort. This study includes an 28-day Screening Period, a 1-day single dose and 7-days multiple doses Treatment Period, and an End of Study Visit occurring approximately 11days (±3 days) after study drug administration.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. · · 2022 · cited 85× · PMID 35956914 · DOI 10.3390/molecules27154964

Verify or expand the search:

Other trials of Hemay005

Trials testing the same drug.

NCT06610890 — Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets · Phase 1 · completed
NCT06610903 — Bioequivalence Test of Hemay005 Tablets · Phase 1 · completed
NCT06380153 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment · Phase 1 · completed
NCT06376474 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage · Phase 1 · recruiting
NCT06145893 — A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease · Phase 3 · recruiting

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Tianjin Hemay Bio-Tech Co., Ltd trials

Trials by the same sponsor.

NCT03577626 — A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03570346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Hemay Bio-Tech Co., Ltd
Last refreshed: 2 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03570346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing